MDCO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MDCO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. The Medicines Co's Operating Income for the three months ended in Sep. 2019 was $-61.37 Mil. The Medicines Co's Interest Expense for the three months ended in Sep. 2019 was $-16.21 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for The Medicines Co's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for The Medicines Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The Medicines Co Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Interest Coverage | Get a 7-Day Free Trial | - | - | - | - | - |
The Medicines Co Quarterly Data | ||||||||||||||||||||
Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
Interest Coverage | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where The Medicines Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The Medicines Co's Interest Coverage for the fiscal year that ended in Dec. 2018 is calculated as
Here, for the fiscal year that ended in Dec. 2018, The Medicines Co's Interest Expense was $-49.41 Mil. Its Operating Income was $-186.34 Mil. And its Long-Term Debt & Capital Lease Obligation was $792.75 Mil.
The Medicines Co did not have earnings to cover the interest expense. |
The Medicines Co's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as
Here, for the three months ended in Sep. 2019, The Medicines Co's Interest Expense was $-16.21 Mil. Its Operating Income was $-61.37 Mil. And its Long-Term Debt & Capital Lease Obligation was $464.99 Mil.
The Medicines Co did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
The Medicines Co (NAS:MDCO) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of The Medicines Co's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander J Denner | director | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Peter Wijngaard | officer: Chief Development Officer | 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Paris Panayiotopoulos | director | ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Geno J Germano | director | 5 GIRALDA FARMS, MADISON NJ 07940 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Christopher T Cox | officer: EVP & Chief Corp. Dev. Officer | CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281 |
Fredric N Eshelman | director, officer: Executive Chairman | PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Armin M Kessler | director | |
Robert J Hugin | director | C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
Hiroaki Shigeta | director | THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Stuart A Kingsley | officer: President and COO | 152 CHESTNUT STREET, WEST NEWTON MA 02465 |
Robert G. Savage | director | C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591 |
Glenn Sblendorio | director, officer: President & CFO | 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
James E Flynn | 10 percent owner, other: Possible Members of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Members of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
From GuruFocus
By Holly LaFon Holly LaFon • 07-17-2019
By gurufocus 10qk • 11-09-2010
By gurufocus 10qk • 11-10-2009
By GuruFocus Research GuruFocus Editor • 03-02-2011
By PRNewswire PRNewswire • 12-03-2019
By PRNewswire PRNewswire • 11-25-2019
By Marketwired Marketwired • 11-25-2019
By PRNewswire PRNewswire • 05-20-2019
By gurufocus • 08-10-2009
By PRNewswire PRNewswire • 11-27-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.